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Major progress has been achieved in our under-
standing of the pathogenesis of Type 2 diabetes (3,
13, 34, 52). Over-nutrition and inactivity promote
insulin resistance. To cope with this increased
demand of insulin secretion, the pancreatic islet
needs to enhance its secretory activity. In most indi-
viduals, such an adaptation does occur during early
stages of increased metabolic stress (characterized
by over-nutrition). Although successful adaptation of
the -cell permits maintenance of normal metabo-
lism throughout life in most subjects, this adaptation
eventually fails in some individuals, depending on
the genetically determined ability of the -cell to
adapt and the severity of the resistance to insulin.
The reasons for this failure to maintain sufficient
insulin secretion are a combined decrease in -cell
mass and defective insulin secretion. Several mecha-
nisms have been proposed to explain this failure,
including ER stress, oxidative stress, amyloid deposi-
tion, lipotoxicity, and glucotoxicity (28, 33, 51, 54,
65). Interestingly, all these factors may induce an
inflammatory response, whereas some may be the
result of the inflammation (16, 17, 19, 31). Initially, an
inflammatory response is probably deployed to pro-
mote -cell repair and regeneration. However, as it
becomes chronic, the situation gets complicated by,
e.g., the activation of auto-inflammatory processes
that may then become deleterious. Interestingly,
similar auto-inflammatory processes occur in
insulin-sensitive tissues. Therefore, Type 2 diabetes
can be considered an auto-inflammatory disease.
Consequently, it can be treated by agents blocking
this vicious cycle such as IL-1 antagonists, or more
downstream by NF-B modulation via salsalate or
similar compounds (15, 59). 
In this article, we will review the evidence for insuli-
tis in Type 2 diabetes, the mechanisms inducing this
inflammatory process, its physiological and patholog-
ical role, and the therapeutic consequences. 
Evidence for an Islet Inflammatory
Process in -Cell Failure During Type
2 Diabetes
In 1967 it was first proposed that Type 2 diabetes is not
solely due to insulin resistance but also to a failure of
the insulin producing -cell to secrete an adequate
amount of insulin (5). Based on numerous investiga-
tions, it is now evident that impaired insulin secretion
is not only an important etiological factor in the patho-
genesis of the disease but also the driving force dictat-
ing the dynamics of the disease. Indeed, although
insulin resistance is present in all stages from pre-dia-
betes to overt diabetes, it remains constant in a single
individual as long as his or her body weight remains
unchanged. In contrast, the onset of diabetes and its
progression is largely determined by the progressive
failure of the pancreatic islet. At a pre-diabetic stage,
insulin production will increase to adapt to the
enhanced demand. When this adaptation fails, dia-
betes occurs. This failure then continues to progress,
and affected individuals will require increasing anti-
diabetic treatment, until eventually all Type 2 diabet-
ics require exogenous insulin to control their
glycemia. In an attempt to understand the underlying
cause of this progressive failure, several mechanisms
have been described. It appears that in all instances
they constitute various components of an inflammato-
ry process. The first evidence for an inflammatory
process in the pancreatic islet arose from the observa-
tion that hyperglycemia induces -cell apoptosis (14).
By unravelling the underlying mechanism, it turned
out that high glucose concentrations induce the Fas
receptor, which in turn is upregulated via glucose-
induced IL-1 production (41, 43, 44). Similarly,
recent evidence shows that fatty acids also promote an
inflammatory response (Refs. 1, 21; and see below).
More downstream, ER stress and oxidative stress also
appear linked to inflammatory events. In support of
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chemokines IL-6 and IL-8 in human islets and CXCL1
(also known as chemokine KC) in mouse islets. These
stimulatory effects of FFAs on proinflammatory medi-
ators are not restricted to islet cells but were also
observed in numerous other cell types such as muscle
(57), macrophage, and adipocyte cell lines (47, 58, 60),
and in coronary artery endothelial cells (62). The com-
bination of FFAs with elevated glucose concentrations
further increases IL-1 expression (1) and the release
of various cyto- and chemokines (21). 
But how do these distinct and “nonspecific” nutri-
ents lead to elevated expression of IL-1 and of IL-1-
regulated cyto- and chemokines in islets? Some
insight was obtained when we examined specific ago-
nists of receptors of the innate immune system, specif-
ically the IL-1/Toll-like receptor (TLR) family (1).
Their stimulation typically leads to activation of pro-
inflammatory processes in response to microbial
pathogens and cell stressors (49). In human islets, spe-
cific TLR2 and TLR4 agonists induce IL-1; however,
the strongest inducer of IL-1 expression is IL-1
itself, which increases its own expression by an auto-
stimulatory mechanism. IL-1 auto-stimulation was
particularly pronounced in purified -cells compared
with whole islets, which consist of different cell types
(2). Furthermore, it was NF-B dependent and could
be interrupted by blocking the IL-1 receptor with the
specific IL-1 receptor antagonist (IL-1Ra) by neutraliz-
ing the receptor ligand or by deleting the intracellular
receptor docking protein required for signal transduc-
tion (Myd88). Using these tools, we could demonstrate
that both elevated glucose concentrations and FFAs
increase IL-1 expression by promoting IL-1 auto-
stimulation via IL-1 receptor activation. Thus IL-1
auto-stimulation via its receptor plays a pivotal role in
the upregulation of intra-islet IL-1 expression pro-
voked by nutrients. Noteworthy, we observed the
highest levels of IL-1 receptor I expression in mouse
islets and in an insulin-secreting -cell line compared
with 22 other rodent tissues (1). These data suggest
that the pancreatic -cell may be exquisitely sensitive
to changes in local IL-1 concentration due to its high
number of IL-1 receptors (1, 55). 
Although these findings are compatible with a role
for the IL-1 system as an amplifier of pro-inflammato-
ry stimuli in islets, it leaves us with the question of how
glucose or FFAs trigger and maintain this process. This
is currently an open question, particularly for glucose,
whereas for FFAs several mechanisms were postulat-
ed. It has been hypothesized that FFAs stimulate 
pro-inflammatory factors via direct activation of the
lipid-sensing TLR2 and TLR4 in various cell types (39).
Results with islets from TLR KO mice indeed show that
FFA-induced pro-inflammatory factors are partly TLR
dependent. Human islets express functional TLR2 and
4 (1, 64), and their activation results in increased
expression of IL-1 and various cyto- and
chemokines. Again, the TLR2/4 response is further
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insulitis in Type 2 diabetes, elevated numbers of
immune cells have been detected in islets of patients
with Type 2 diabetes in conjunction with increased
levels of cytokines and chemokines (2, 21, 53). Of note,
every animal model of Type 2 diabetes investigated to
date displays islet immune cell infiltration (19, 21).
Furthermore, a strong argument for the occurrence of
an inflammatory process in islets is the well described
fibrosis observed in tissue sections of patients with
Type 2 diabetes, characterized by amyloid deposits.
Indeed, fibrosis is a hallmark of the end stage of a
chronic inflammatory process. Although the concept
of insulitis is recent in Type 2 diabetes, it is well estab-
lished in Type 1 diabetes and was considered as
pathognomonic. Although the precise aetiology of the
insulitis in both diabetes types remains to be fully
understood, differences certainly exist; for example,
Type 1 diabetes is a more autoimmune-mediated
process. However, a common final effector pathway
seems to be activated in both types of diabetes (17).
Keeping in mind that metabolic stress is a more recent
threat than viruses or other possible causes of Type 1
diabetes, it is not surprising that islets respond with
similar mechanisms developed over their long period
of evolution. Of interest is the predominant role of IL-
1, which is upregulated in islets of patients with both
Type 1 and Type 2 diabetes (2, 43, 45). This master
cytokine regulates numerous cytokines and also
chemokines (Refs. 12, 20; and see below). Thereby, it
contributes to the recruitment of immune cells imple-
menting a broad inflammatory response. Of note is
that IL-1 will also induce itself in -cells, engender-
ing a vicious cycle (Ref. 2; and see below). Thus insuli-
tis may be considered as an integral component of the
pathology observed in Type 2 diabetes, and its
dependence on IL-1 supports the concept of an auto-
inflammatory nature of the disease. 
Regulation of IL-1 Expression by
Nutrients in Human Islets
Elevation of circulating nutrients such as glucose and
free fatty acids (FFAs) induce an inflammatory process
within numerous tissues in the body (32, 68). The first
demonstration that a high glucose concentration
indeed induces IL-1 release was obtained with
human islets (43), with similar observations following
in rat islets (24), retinal cells (70), and human mono-
cytes (8). Moderately elevated glucose concentrations
(11 mM) were sufficient to induce transcriptional acti-
vation of IL-1 expression in human islets (2). 
More recently, we also found that long-chain FFAs
induce several cyto- and chemokines in human and
rodent islets (1). Oleate, palmitate and stearate, which
are the most abundant FFAs in human nutrition, and
hence in the circulation, stimulate IL-1 expression
when added individually or as mixtures. Similarly,
FFAs induced the IL-1-dependent cyto- and
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amplified by IL-1 auto-stimulation. Thus the IL-1 sys-
tem in islets not only amplifies the response to circulat-
ing nutrients but also to specific TLR agonists.
Intriguingly, it was observed that obese subjects and
rodents display elevated levels of circulating gut flora-
derived endotoxins that could potentially trigger TLRs
(4, 7), or, alternatively, inflammatory factors derived
from other organs could stimulate TLRs in islets. To this
end, it was recently shown that serum amyloid A binds
to TLR2 (6), which is prominently expressed on purified
human and rodent -cells (J. Ehses, unpublished data,
and Ref. 1). Alternative to TLR stimulation, FFA metabo-
lites such as sphingosines have also been implicated in
the induction of a pro-inflammatory response (29). 
Overall, we conclude that elevated concentrations
of various nutrients such as glucose and FFAs may
activate the IL-1 system in pancreatic islets. Probably
depending on duration of the exposure and the com-
position and concentrations of the ambient nutrients,
sufficient amounts of IL-1 may be triggered to over-
come the protective effect of the naturally occurring
IL-1Ra (9), thus activating the potent IL-1 receptor.
This auto-stimulation engenders a vicious cycle pre-
cipitating a broad inflammatory process, as detailed in
the next section (see also Figure 1). 
IL-1 is a Master Regulator of Tissue
and Islet Inflammation in 
Type 2 Diabetes
It has been known for a long time that obesity and
Type 2 diabetes are associated with chronic activation
of the innate immune system (50). Indeed, this activa-
tion appears to be systemic, given the increased levels
of circulating cytokines and chemokines correlating
with the disease and their potential in predicting Type
2 diabetes onset (30, 61). Local tissue inflammation is
increasingly recognized in the pathology of both obe-
sity-associated insulin resistance and -cell failure in
human Type 2 diabetes (16, 68). In all cases, this
inflammation is characterized by increased tissue-
infiltrating macrophages (21, 66). Indeed, two 
independent studies have now shown increased islet-
associated CD68+ cells in Type 2 diabetic patients (21,
53). Furthermore, data from laser-captured -cells
from patients with Type 2 diabetes have indicated
increased expression of IL-1mRNA and chemokines,
potentially responsible for this immune cell infiltra-
tion (2, 46). However, the contribution of IL-1 in the
regulation of this islet inflammatory response in vivo
was unknown until recently. 
A number of animal models of Type 2 diabetes have
now been characterized to various degrees regarding
the presence of an islet inflammatory signature,
including the GK rat, the high-fat diet (HFD)-fed
mouse, the db/db mouse, the Psammomys Obesus ger-
bil, the fatty Zucker rat, and the Cohen rat (19, 21, 40,
67). In a number of these models, increased islet IL-1
expression and increased numbers of islet
macrophages are an underlying feature. We recently
extensively characterized the islet inflammatory
process in the GK rat, showing increased islet expres-
sion of IL-1 and other pro-inflammatory cytokines
(IL-6, TNF), increased expression of a number of
chemokines (CXCL1/ KC, MCP-1, MIP-1), together
with immune cell infiltration in the islet (20). Since an
important property of IL-1 in auto-inflammatory dis-
eases is to increase the local expression of chemokines
and adhesion molecules (12), we investigated the role
of IL-1 in tissue inflammation in the GK rat, with a
focus on the pancreatic islet. Elevated IL-1 mRNA
levels were found in 2-mo-old GK rat islets and liver,
with no increases in skeletal muscle or adipose tissue.
To assess the biological impact of this finding, we
blocked IL-1 activity with IL-1Ra in vitro and in vivo.
IL-1Ra was able to suppress GK islet IL-6 and
chemokine secretion (CXLC1/KC, MCP-1, and MIP-
1) in vitro, indicating that IL-1 activity is partially
responsible for driving GK islet cytokine and
chemokine expression. Treatment of GK rats with IL-
1Ra, administered via either mini-osmotic pumps or
subcutaneous injections, reduced fed hyperglycemia
over the 4 wk of treatment. This was due to both
peripheral and islet anti-inflammatory effects impact-
ing on both insulin sensitivity and -cell function in a
dose-dependent manner. Indeed, analysis of liver and
islet inflammation in high-dose IL-1Ra-treated ani-
mals (100 mg/kg day IL-1Ra) indicated reductions in
inflammatory markers in both tissues. Specifically in
the islet, IL-1Ra reduced islet cytokine and chemokine
327PHYSIOLOGY • Volume 24 • December 2009  • www.physiologyonline.org
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FIGURE 1. Regulation of IL-1 in islets by metabolic stress
Elevated glucose and FFA initially initiate the expression and release of low levels of IL-
1 (stimulation) required for the adaptive response of islet cells. Continuous or pro-
longed stimulation with nutrients (metabolic stress) will lead to the activation of the IL-
1RI leading to a further increase of IL-1 by an autostimulatory process and to the pro-
duction of IL-1-dependent cyto- and chemokines (amplification). Autocrine and paracrine
activation will precipitate of a broad inflammatory response including elevated cyto- and
chemokine production, attraction of macrophages, apoptosis and amyloidosis, fibrosis,
and impaired insulin secretion (precipitation). 
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IL-6 promoted -cell proliferation and prevented -cell
apoptosis due to metabolic stress while exacerbating -
cell apoptosis. Thus, in contrast to the negative effects
on the -cell, IL-6 acts as a growth and survival factor
and promotes glucagon secretion in the -cell. 
Further studies in vivo supported this hypothesis. For
this, we studied the role of IL-6 in the setting of obesity
and insulin resistance by feeding wild-type and IL-6 KO
mice HFD. Although HFD increased systemic IL-6 lev-
els in wild-type animals, this did not occur in IL-6 KO
animals. Most striking, IL-6 KO mice did not show
increased -cell mass under these conditions, demon-
strating that IL-6 signaling is necessary for the stimulat-
ing effect of HFD on -cell mass. Consistent with these
-cell-specific findings, IL-6 KO animals displayed
reduced fasting glucagon levels relative to wild-type
animals on HFD. However, in contrast to the expected
improvement in glucose tolerance in these animals, IL-
6 KO mice on HFD displayed fed hyperglycemia,
impaired glucose tolerance, and impaired glucose-
stimulated insulin secretion compared with diet-
matched wild-type animals. This effect has previously
been published using IL-6 KO animals from the same
source that we used (11). Since insulin sensitivity was
similar among genotypes, the phenotype can be attrib-
uted to impaired -cell function and suggests a role for
the -cell in maintaining -cell function in vivo. Indeed,
recent reports support this notion. Thus -cell expres-
sion of prohormone convertase-1/3 (allowing the -cell
to produce GLP-1) or overexpression of the glucagon
receptor on -cells promotes improved insulin secre-
tion (25, 69), thus supporting the hypothesis that the
pancreatic -cell can regulate -cell function in vivo in
a paracrine manner. That -cell mass expansion is an
important feature of the pathology of Type 2 diabetes
was shown in Type 2 diabetic baboons, in which
increased -cell proliferation and mass together with
hyperglucagonemia was recently described as part of
the islet remodeling process (26). 
Thus IL-6 regulation of the pancreatic -cell repre-
sents a novel endocrine loop in the regulation of 
glucose homeostasis. Although it appears that this
mechanism may exist to compensate for impaired -
cell function in the setting of obesity and/or Type 2
diabetes, it cannot be ignored that elevated IL-6 levels
may also drive the relative hyperglucagonemia of dia-
betic patients. How this pathway contributes to the IL-
6-mediated effects during physiology [e.g., during
exercise, where systemic IL-6 levels are elevated (23)]
or during the pathophysiology of obesity and diabetes
in humans remains to be examined. 
Role of Insulitis in Obesity and Type
2 Diabetes: From Islet Adaptation
to Failure
Inflammation is not in itself a disease but a manifesta-
tion of a disease. Initially, it has beneficial effects such
328 PHYSIOLOGY • Volume 24 • December 2009  • www.physiologyonline.org
expression, with concomitant decreases in islet
macrophage infiltration. Supportive of this reduction
in immune cell infiltration, further work has indicated
that markers of endothelial cell activation, such as
adhesion molecule expression (Vcam1), were also
suppressed by IL-1Ra treatment (36). Finally, 
reduction in islet inflammation correlated with
improvements in proinsulin to insulin processing in
IL-1Ra-treated animals. Since this IL-1Ra intervention
study in the GK rat had minimal effects on -cell mass,
while improving -cell insulin processing and 
hyperglycemia, we propose that IL-1 drives tissue
inflammation, which then impacts on both insulin
sensitivity and -cell functional mass in Type 2 dia-
betes. However, this does not exclude some additional
direct cytotoxic effects. 
Interestingly, IL-1Ra treatment of the GK rat also
reduced islet IL-1 expression itself, supporting that
the auto-stimulatory role of IL-1 in the islet (as
described above) plays an important role in the islet
inflammatory process in vivo. 
In summary, both our in vitro data on human and
rodent islets and our in vivo studies on the GK rat sup-
port a central role for IL-1 in driving the expression of
tissue proinflammatory cytokines and chemokines
that subsequently attract immune cells to islets. This
inflammatory process leads to impairment of -cell
function. These data support the concept that Type 2
diabetes is an IL-1-driven auto-inflammatory disease. 
IL-6 Regulation of the Pancreatic 
-Cell
Pancreatic islet pathology in Type 2 diabetes is charac-
terised not only by reduced -cell function and mass
but also by increased proportion of -cells relative to
-cells, together with relative hyperglucagonemia due
to -cell dysfunction (10, 63, 71). Having recently
found elevated IL-6 levels in pancreatic islets of mod-
els of Type 2 diabetes (20, 21), we re-explored its role
in the regulation of - and -cells (22). 
We confirmed the previously published detrimental
effects of IL-6 on insulin secretion in both human and
rodent islets in vitro (35). Beyond this, however, we
found that the glucagon-producing -cell is a primary
target of IL-6. Islet -cells express the IL-6 receptor and
functionally respond to IL-6 kinetically prior to -cells.
IL-6 was found to increase glucagon secretion under
fasting conditions (low glycemia) in isolated islets and
when systemically administered in vivo. Furthermore,
REVIEWS
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as preventing spread of infection or promoting regen-
eration. However, if prolonged or excessive, it may
exacerbate disease by tissue destruction. It is likely
that, in the case of islet inflammation in Type 2 dia-
betes, similar phenomena occur. Indeed, the
endocrine pancreas has a remarkable capacity to
adapt to conditions of increased insulin demand as
encountered in obesity and pregnancy by increasing
its functional mass. This may be triggered by limited
hyperglycemic events that would provoke -cell pro-
duction of very low concentrations of IL-1 followed
by Fas upregulation (41, 42). At low concentrations of
IL-1 and in the presence of FLIP, Fas engagement
would lead to -cell proliferation and enhanced func-
tion via NF-B and PDX1 (56). Indeed, NF-B has been
reported to have beneficial effects on both insulin
secretion and -cell proliferation (27, 48). If this
response becomes excessive due to prolonged or repet-
itive exposure to nutrients, this initially adaptive
process may become deleterious. IL-1 will then
decrease FLIP and Fas engagement and switch to pro-
mote deleterious effects. In addition, IL-1 initiates the
vicious cycle of inducing itself and promoting an
enhanced release of chemokines, which leads to
recruitment of macrophages (2). Possibly, these
macrophages then produce a high amount of IL-1 (67)
and other cytotoxic factors, which then impair the func-
tion of the -cell. It is important to note that these
mechanisms may be responsible for both decreased 
-cell mass and impaired function. Depending on
duration and magnitude of the effect as well as the indi-
vidual regenerative capacity, the functional impairment
may predominate over the more definitive decrease in
-cell mass. Interestingly, such an auto-inflammatory
process occurs also in the insulin-sensitive tissues and
in end organs such as kidney, eye, and the vasculature.
Therefore, tissue inflammation may not only underlie
-cell failure and insulin resistance but also participate
directly in the complications of diabetes, such as
nephropathy, retinopathy, and cardiovascular disease. 
Clinical Validation and Therapeutic
Consequences
Based on the above-described predominant role of IL-
1, we initiated clinical trials of IL-1 antagonism in
Type 2 diabetes. In a proof-of-concept study, the natu-
rally occurring antagonist of IL-1, IL-1Ra, was tested
in a placebo-controlled study of 70 patients (38). At 13
wk, glycated hemoglobin was significantly improved
due to enhanced -cell secretory function.
Remarkably, the improvement promoted by IL-1
blockade lasted for at least 39 wk following treatment
withdrawal (37), thus reflecting the disease-modifying
potential of this therapy. Novel therapeutic approach-
es designed to modulate IL-1 are under development
with agents lasting a month or longer (18). Rather than
just palliating hyperglycemia, IL-1 antagonism may
represent a novel treatment principle directed against
the pathogenesis that underlies diabetes mellitus,
whereby the progressive decline in functional -cell
mass could be prevented or even reversed. Due to the
auto-inflammatory nature of the whole metabolic syn-
drome and based on preclinical studies, it is expected
that IL-1 antagonism will also enhance insulin sensitiv-
ity and prevent complications like blindness, cardiovas-
cular events, and nephropathy. Numerous ongoing
clinical studies are based on this assumption. 
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